Showing results (2031-2040 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|September 1, 1995
Immunoscintigraphy of colorectal cancer using 111In-labeled monoclonal antibody to mucinH Sakahara, H Onodera, M Shirato, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1995
Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3H B Kwa, A H Verhoeven, J Storm, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccineD Shrayer, H Bogaars, V J Hearing, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft modelsM G Rosenblum, L Cheung, K Mujoo, et al.
Cancer Immunology, Immunotherapy : CII|May 1, 1995
Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCSE Masuda, H Maeda
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Interleukin-2 in cancer treatment: disappointing or (still) promising? A reviewR A Maas, H F Dullens, W Den Otter
Cancer Immunology, Immunotherapy : CII|January 1, 1993
HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patientsR A Janssen, J Buter, E Straatsma, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Characterization of the exogenous interleukin-2 requirements for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearersM Rubin, M B Mokyr
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?W Fujimaki, J R Griffin, E S Kleinerman
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancerG E Goodman, I Hellstrom, D E Yelton, et al.
Pageof 652